

Purdue Pharma Docket Submission Index

Date	Docket Title / Description		Brief Summary
May 25, 2021	2921	Early Objection / Statement	Initial survivor objection raising prescribed-opioid harm, prevention, and patient-safety concerns.
May 27, 2021	2950	Supplemental Objection / Statement	Expanded early arguments on chronic-pain patients, non-addicted dependency, rural care, and unit-dose packaging.
July 1, 2021	3102	Supplemental Statement / Objection	Detailed personal and pharmacy-background narrative supporting packaging reform and non-pharmaceutical care.
Aug. 13, 2021	3559	Formal Objection / Main Points	Structured objections: long-acting opioids, unit-dose packaging, rural alternatives, stigma, and abatement bureaucracy.
Sept. 7, 2021	3737	Debtors' Response / Related Filing	Purdue formally acknowledged and responded to your objections and hearing testimony.
Feb. 25, 2022	4394	<i>Statement on the Eighth Monitoring Report</i>	Criticized regulatory "education," medical-marijuana exclusion, stigma, and fairness for claimants with receipts.
Feb. 25, 2022	4405	Letter to Debtors	Expanded lived-experience and community-restoration arguments.
Mar. 2, 2022	4406	Letter of Apology / Vision Statement	Apologized for rhetoric and outlined recovery, Grace Space, Devotion With Motion, and community-healing goals.
Mar. 8, 2022	4489	<i>Objection to the Motion to Approve the Settlement Term Sheet</i>	Objected to carve-outs, bureaucracy, victim caps, and lack of priority for direct victims with receipts.
Aug. 2, 2022	4996	Motion re: EO 13985 / Recovery Funding	Objected to ideological conditions on recovery funds and requested survivor participation in funding policy.
Aug. 4, 2022	5002	Submission of EO 13985 Motion	Re-submitted the EO 13985 motion and "Shut the Front Door!" essay for court consideration.
Nov. 9, 2022	5226	U.S. Opposition to McGaha Motions	DOJ opposed your EO 13985 motions on standing and mischaracterization grounds.

Date	Docket Title / Description	Brief Summary
Nov. 15, 2022	5241 Response to U.S. Opposition	Replied to DOJ arguments and challenged standing, equity framing, and exclusion of survivor voices.
Apr. 27, 2023	5581 Packaging / Legislative Reform Filing	Consolidated unit-dose packaging advocacy, legislative outreach, and earlier reform arguments.
Nov. 17, 2023	6021 Statement in Support of Supreme Court Review	Supported Supreme Court review of nonconsensual releases and preserved prior objections.
Jan. 2, 2024	6101 Statement by Individual Personal Injury Claimant	Focused on GOODFAITH, consent, fees, “Difficulty by Design,” and unfair treatment of direct victims.
July 4, 2024	6520 Request to Appear and Participate	Requested participation in post-Supreme Court hearings and mediation.
July 15, 2024	6545 Notice / Mediation Participation Request	Requested mediation inclusion, notice, ADA-style accommodation, and preservation of rights.
July 19, 2024	6556 <i>Amended Notice of Appearance and Request for Service of Papers</i>	Requested full notice and preserved individual rights in mediation and related proceedings.
July 19, 2024	6557 <i>Amended Notice of Appearance and Request for Service of Papers</i>	Same notice with certificate of service added.
Aug. 9, 2024	6607 <i>Request to Have Address and Email Address Redacted</i>	Requested privacy protection and redaction of personal information from public docket filings.
Sept. 2, 2024	6666 Mediation / Abatement Definitions Objection	Challenged opioid definitions, abatement drug carve-outs, and dependency-system incentives.
Sept. 13, 2024	6700 Objection to UCC Sole Standing Authority	Objected to institutional control while direct victims were excluded from meaningful input.
Dec. 5, 2024	6996 Request for Separate Class	Requested separate treatment for prescribed-opioid victims distinct from illegal-drug narratives.
Apr. 2, 2025	7350 Objection re: PI/TPP Claims Administrators	Critiqued insurers, government entities, and institutional reimbursement over direct victim compensation.

Date	Docket Title / Description	Brief Summary
Apr. 7, 2025	7361 <i>Amended Objection/Response to Joint Motion...</i>	Refined systemic-enabling argument against reimbursing TPPs/government at victims' expense.
May 11, 2025	7432 <i>Motion for Full-Satisfaction of Claim and Objection to Discharge...</i>	Argued fraud-based personal injury claims require full satisfaction and should not be discharged.
May 19, 2025	7451 <i>Amended Full-Satisfaction / Discharge Objection</i>	Sharpened nondischargeability, coercion, GOODFAITH, and survivor-fairness arguments.
June 11, 2025	7522 <i>Objection to the Approval of Disclosure Documents & Plan</i>	Proposed unit-dose packaging, insurance reform, survivor roles, and truth-based reform.
June 16, 2025	7595 <i>Objection to Disclosure Statement and Plan</i>	Objected to narrative manipulation and lack of structural prevention in the new plan.
July 20, 2025	7676 <i>Notice of Appearance and Intent to Provide Expert Testimony</i>	Introduced expert testimony on negligent bulk narcotic packaging.
July 25, 2025	7683 <i>Filed Expert Testimony</i>	Formally docketed negligent-packaging expert testimony.
Aug. 5, 2025	7724 <i>Expert Testimony with Scientific Support</i>	Expanded packaging testimony with CDC guidance and medication-adherence research.
Aug. 11, 2025	7737 <i>Expert Testimony of Carrie L. McGaha, Pro Se Claimant</i>	Finalized expert testimony advocating patient-friendly unit-dose narcotic packaging.
Oct. 10, 2025	7993 <i>Amended Certificate of Service / Expert Testimony</i>	Served and preserved expert testimony through the formal expert-report process.
Apr 15, 2026	9039 <i>Response to Settlement with McKinsey and Co</i>	For the Record
Apr 15, 2026	9040 <i>Submission of Victim Impact Statement for Criminal Court</i>	For the Record